Chennai Meena

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE889F01017
  • NSEID:
  • BSEID: 523489
INR
33.90
0.93 (2.82%)
BSENSE

Apr 02

BSE+NSE Vol: 1.89 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.89 k (5.98%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

57.10%

how big is Chennai Meena?

06-Jun-2025

As of Jun 06, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 23.52 Cr, with net sales of 34.82 Cr and a net profit of -1.37 Cr over the latest four quarters. The standalone balance sheet shows shareholder's funds of -0.33 Cr and total assets of 22.81 Cr.

As of Jun 06, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 23.52 Cr, classifying it as a Micro Cap company.<BR><BR>As of Jun 06, the company reported a sum of Net Sales for the latest 4 quarters amounting to 34.82 Cr and a Net Profit of -1.37 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Standalone balance sheet shows Shareholder's Funds of -0.33 Cr and Total Assets of 22.81 Cr.

Read More

What does Chennai Meena do?

06-Jun-2025

Chennai Meenakshi Multispeciality Hospital Ltd, established in 1990, operates in the healthcare sector as a micro-cap company with a market cap of Rs 23 Cr. As of March 2025, it reported net sales of 9 Cr and a net profit of 0 Cr.

Overview:<BR>Chennai Meenakshi Multispeciality Hospital Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1990 and was formerly known as Devaki Hospital Limited until its name change in October 2007. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 9 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: Rs 23 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -4.96<BR>- Return on Equity: 98.56%<BR>- Price to Book: -16.83<BR><BR>Contact Details:<BR>- Address: New No 70 Old No 149, Luz Church Road Mylapore Chennai Tamil Nadu : 600004<BR>- Tel: 91-044-42938938<BR>- Email: cmmhospitals@gmail.com<BR>- Website: https://cmmh.in

Read More

Has Chennai Meena declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Chennai Meena?

03-Jun-2025

Chennai Meena's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, Gian Lifecare, Vanta Bioscience, and Clinitech Lab. In terms of management risk, growth ratings, and capital structure, they vary from excellent to below average, with Chennai Meena showing a 1-year return of -2.80%.

Peers: The peers of Chennai Meena are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, Gian Lifecare, Vanta Bioscience, Clinitech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Clinitech Lab, and Average management risk is noted at Family Care. Below Average management risk is seen at Gian Lifecare, while Vanta Bioscience and Chennai Meena do not qualify. Growth ratings show Good growth at Family Care, Average growth at Poly Medicure, Indegene, and Gian Lifecare, and Below Average growth at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Clinitech Lab, with Chennai Meena and Vanta Bioscience not qualifying. Excellent capital structure is noted for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, and Gian Lifecare, while Good capital structure is observed at Clinitech Lab, and Chennai Meena and Vanta Bioscience do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.17%, while the lowest is Vanta Bioscience at -54.78%. Chennai Meena's 1-year return is -2.80%, which is higher than Vanta Bioscience but lower than Poly Medicure. Additionally, the six-month returns for Family Care, Chennai Meena, Gian Lifecare, Vanta Bioscience, and Clinitech Lab are all negative.

Read More

Is Chennai Meena overvalued or undervalued?

09-Jun-2025

As of May 31, 2024, Chennai Meena's valuation has shifted from attractive to risky due to negative financial metrics, including a PE ratio of -17.17 and an EV to EBITDA of -30.42, indicating it is overvalued and underperforming compared to peers like Max Healthcare and Apollo Hospitals, as well as the Sensex.

As of 31 May 2024, the valuation grade for Chennai Meena has moved from attractive to risky, indicating a significant deterioration in its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of -17.17, an EV to EBITDA of -30.42, and a ROCE of -11.43%. These negative ratios suggest that the company is struggling to generate profits and manage its capital effectively.<BR><BR>In comparison to its peers, Chennai Meena's valuation stands out unfavorably. For instance, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals shows a PE of 69.03, both indicating a much stronger market position. The stark contrast in valuation ratios highlights that Chennai Meena is not only underperforming but also facing significant challenges relative to its competitors. Additionally, the company's stock has underperformed the Sensex over the past year, with a return of -8.52% compared to the Sensex's 7.58%, reinforcing the notion that it is currently overvalued.

Read More

What is the technical trend for Chennai Meena?

09-Jun-2025

As of May 12, 2025, Chennai Meena's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 12 May 2025, the technical trend for Chennai Meena has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are bearish. The KST reflects a mildly bullish weekly trend but is mildly bearish monthly. The Dow Theory shows a mildly bullish weekly trend with no trend on the monthly. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the MACD and KST on the weekly chart.

Read More

Who are in the management team of Chennai Meena?

16-Jul-2025

As of March 2023, the management team of Chennai Meena consists of R Gomathi as Managing Director and K. Meyyanathan, N. Rajkumar, and Jayanthi Radhakrishnan as Independent Directors.

As of March 2023, the management team of Chennai Meena includes the following individuals:<BR><BR>1. R Gomathi - Managing Director<BR>2. K. Meyyanathan - Independent Director<BR>3. N. Rajkumar - Independent Director<BR>4. Jayanthi Radhakrishnan - Independent Director<BR><BR>R Gomathi serves as the Managing Director, while the other three members hold positions as Independent Directors.

Read More

Who are the top shareholders of the Chennai Meena?

17-Jul-2025

The top shareholders of Chennai Meena are Jayanthi Radhakrishnan with 25.59%, followed by public shareholder Vijayan Abinaya at 10.06%. Individual investors own 60.51%, with no pledged promoter holdings or foreign institutional investors.

The top shareholders of Chennai Meena include Jayanthi Radhakrishnan, who holds the highest stake at 25.59%. The highest public shareholder is Vijayan Abinaya, with a holding of 10.06%. Additionally, individual investors collectively own 60.51% of the company. There are no pledged promoter holdings or foreign institutional investors involved, and mutual funds hold a small percentage through one scheme at 0.14%.

Read More

Are Chennai Meena latest results good or bad?

13-Aug-2025

Chennai Meenakshi Multispeciality Hospital's latest results for June 2025 are disappointing, with a Profit After Tax of Rs -0.74 crore and a significant decline in operational efficiency, indicating ongoing financial challenges.

Chennai Meenakshi Multispeciality Hospital's latest financial results for the quarter ending June 2025 are quite disappointing. The company reported a Profit After Tax (PAT) of Rs -0.74 crore, which is a significant decline compared to the previous quarters. This represents a decrease of 116.1% from the average PAT of Rs -0.34 crore over the last four quarters, indicating ongoing challenges in profitability.<BR><BR>Additionally, the Operating Profit (PBDIT) fell to Rs -0.51 crore, marking the lowest point in five quarters, and the Operating Profit Margin has dropped to -5.90%. This suggests a deterioration in operational efficiency. The Profit Before Tax less Other Income (PBT) was also at Rs -1.03 crore, the lowest in the last five quarters, further highlighting the concerning trend in the company's financial performance.<BR><BR>Overall, the results indicate significant challenges in both operational and financial health for Chennai Meenakshi Multispeciality Hospital, suggesting that the latest results are indeed bad.

Read More

When is the next results date for Chennai Meena?

04-Nov-2025

The next results date for Chennai Meena is 13 November 2025.

The next results date for Chennai Meena is scheduled for 13 November 2025.

Read More

How has been the historical performance of Chennai Meena?

14-Nov-2025

Chennai Meena's historical performance shows declining net sales and profits, with revenue dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, and a shift from profit to loss in operating profit and net profit. Despite these challenges, total liabilities and cash flow from operations remained stable.

Answer:<BR>The historical performance of Chennai Meena shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Chennai Meena's net sales decreased from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, reflecting a decline in revenue. The total operating income followed a similar trend, dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25. The company experienced an operating profit (PBDIT) decline, moving from 3.35 Cr in Mar'23 to a loss of 0.21 Cr in Mar'25. Consequently, the profit before tax also fell from 1.28 Cr in Mar'23 to a loss of 1.43 Cr in Mar'25, leading to a profit after tax decline from 0.89 Cr to a loss of 1.37 Cr in the same period. The company's total liabilities remained relatively stable, with a slight decrease from 22.81 Cr in Mar'24 to 22.51 Cr in Mar'25. Cash flow from operating activities remained consistent at 2.00 Cr from Mar'22 to Mar'25, while the closing cash and cash equivalents were stable at 2.00 Cr in Mar'25. Overall, Chennai Meena's financial performance indicates challenges in profitability despite stable cash flow and liabilities.

Read More

Should I buy, sell or hold Chennai Meena?

16-Nov-2025

Why is Chennai Meena falling/rising?

03-Dec-2025

As of 03-Dec, the stock price of Chennai Meenakshi Multispeciality Hospital Ltd is at 45.00, showing mixed performance with a recent weekly gain but a significant decline over the past month. The stock's erratic trading patterns and reduced investor participation suggest ongoing weakness and stagnation in its price.

As of 03-Dec, the stock price of Chennai Meenakshi Multispeciality Hospital Ltd is currently at 45.00, with no change from the previous trading session. The stock has shown mixed performance over different time periods. In the last week, it has increased by 0.22%, outperforming the Sensex, which fell by 0.59%. However, over the past month, the stock has declined by 13.88%, while the Sensex has gained 1.34%. Year-to-date, the stock is up by 7.14%, but it has decreased by 10.05% over the past year, contrasting with the Sensex's 5.27% increase.<BR><BR>Despite the recent weekly gain, the stock's performance has been erratic, with it not trading on one day out of the last 20 days. Additionally, there has been a significant drop in investor participation, with delivery volume on 26 November falling by 99.38% compared to the 5-day average. This decline in trading activity may indicate reduced investor interest, which could contribute to the stock's overall downward trend in the longer term. Furthermore, while the stock is trading above its 5-day, 100-day, and 200-day moving averages, it is below its 20-day and 50-day moving averages, suggesting some short-term weakness.<BR><BR>Overall, the combination of declining investor participation, erratic trading patterns, and a significant drop in performance over the past month may explain the current stagnation in the stock price of Chennai Meenakshi Multispeciality Hospital Ltd.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 11.27% and Operating profit at 0% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at 0 times
2

Flat results in Sep 25

3

Risky - Negative EBITDA

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 25 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

55

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.30

stock-summary
Return on Equity

35.41%

stock-summary
Price to Book

-9.58

Revenue and Profits:
Net Sales:
9 Cr
(Quarterly Results - Dec 2025)
Net Profit:
-1 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.03%
0%
-29.03%
6 Months
-19.95%
0%
-19.95%
1 Year
9.57%
0%
9.57%
2 Years
-10.72%
0%
-10.72%
3 Years
82.75%
0%
82.75%
4 Years
47.71%
0%
47.71%
5 Years
248.05%
0%
248.05%

Chennai Meena for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary

Closure of Trading Window

30-Mar-2026 | Source : BSE

Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 as amended read with Companys Code on Prevention of Insider Trading it is hereby informed that the Trading window for the purpose of transaction in the Companys shares(s) by the Directors Designated Employees other insiders of the Company and their relatives will remain closed from 1st April 2026 till the completion of 48 hours after declaration of the Audited financial results for the Quarter/Year ended 31st March 2026. Accordingly all the designated employees other insiders of the company (including Directors) and their relative have been intimated not to trade in the Companys share(s) during the aforesaid period of closure of Trading Window. The date of Board Meeting to consider approve and take on record the Audited financial results for the Quarter/Year ended 31st March 2026 shall be intimated to the Stock Exchange in due course.

Announcement under Regulation 30 (LODR)-Newspaper Publication

24-Mar-2026 | Source : BSE

Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations 2015 as amended from time to time and in accordance with the SEBI Circular HO/38/13/11(2)2026 MIRSD-POD/I/3750/2026 dated 30th January 2026 we hereby enclose the copies of the newspaper advertisement published for the Equity Shareholder of the Company regarding the Special Window for Transfer and Dematerialisation of Physical Securities. The said advertisement was published in Financial Express & Makkal Kural Newspaper on Thursday 19th March 2026.

Announcement Under Regulation 30 (LODR)-Updates (Details Of Payment Of Fines For Non-Compliance With Reg 6(1) Of SEBI LODR.

23-Mar-2026 | Source : BSE

With reference to the above-mentioned subject we Chennai Meenakshi Multispeciality Hospital Limited wish to submit that we have paid the penalty levied for the delayed appointment of a Company Secretary and Compliance Officer under Regulation 6(1)of the SEBI (LODR) Regulations 2015 and as a consequence of rejection of our waiver application. Kindly de-freeze our promoters shareholding at the earliest. Scrip Code : 523489 Regulation & Quarter : Reg 6(1) & Dec 2025 Bank UTR number : 520-260-32334788386 Date of payment : 23/3/2026 Amount paid : Rs. 93220/- TDS deducted if any : Nil Net Amount paid : Rs. 93220/-

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.57%
EBIT Growth (5y)
-11.92%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
2.46
Net Debt to Equity (avg)
-2.30
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
12.23%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
55
Price to Book Value
-9.85
EV to EBIT
-24.78
EV to EBITDA
-31.22
EV to Capital Employed
9.38
EV to Sales
0.86
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-40.54%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 1 Schemes (0.14%)

FIIs

Held by 0 FIIs

Promoter with highest holding

Jayanthi Radhakrishnan (25.59%)

Highest Public shareholder

Mahendra Girdharilal Wadhwani (2.65%)

Individual Investors Holdings

39.83%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -3.80% vs 9.48% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -460.00% vs 120.27% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.11",
          "val2": "9.47",
          "chgp": "-3.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.33",
          "val2": "0.30",
          "chgp": "-210.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.22",
          "val2": "0.23",
          "chgp": "-4.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.54",
          "val2": "0.15",
          "chgp": "-460.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3.62%",
          "val2": "3.17%",
          "chgp": "-6.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 7.73% vs -9.52% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 44.34% vs -1,866.67% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.12",
          "val2": "16.82",
          "chgp": "7.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.22",
          "val2": "-0.17",
          "chgp": "-29.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "0.46",
          "chgp": "-2.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.59",
          "val2": "-1.06",
          "chgp": "44.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.21%",
          "val2": "-1.01%",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 6.16% vs -10.50% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 33.14% vs -8,550.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.23",
          "val2": "25.65",
          "chgp": "6.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.55",
          "val2": "-0.55",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.67",
          "val2": "0.69",
          "chgp": "-2.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-1.13",
          "val2": "-1.69",
          "chgp": "33.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.02%",
          "val2": "-2.14%",
          "chgp": "0.12%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -8.85% vs -1.39% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -218.60% vs -148.31% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34.82",
          "val2": "38.20",
          "chgp": "-8.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.21",
          "val2": "1.71",
          "chgp": "-112.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.91",
          "val2": "0.92",
          "chgp": "-1.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-1.37",
          "val2": "-0.43",
          "chgp": "-218.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.60%",
          "val2": "4.48%",
          "chgp": "-5.08%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary
Dec'25
Sep'25
Change(%)
Net Sales
9.11
9.47
-3.80%
Operating Profit (PBDIT) excl Other Income
-0.33
0.30
-210.00%
Interest
0.22
0.23
-4.35%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.54
0.15
-460.00%
Operating Profit Margin (Excl OI)
-3.62%
3.17%
-6.79%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -3.80% vs 9.48% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -460.00% vs 120.27% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
18.12
16.82
7.73%
Operating Profit (PBDIT) excl Other Income
-0.22
-0.17
-29.41%
Interest
0.45
0.46
-2.17%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.59
-1.06
44.34%
Operating Profit Margin (Excl OI)
-1.21%
-1.01%
-0.20%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 7.73% vs -9.52% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 44.34% vs -1,866.67% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary
Dec'25
Dec'24
Change(%)
Net Sales
27.23
25.65
6.16%
Operating Profit (PBDIT) excl Other Income
-0.55
-0.55
Interest
0.67
0.69
-2.90%
Exceptional Items
0.00
0.00
Standalone Net Profit
-1.13
-1.69
33.14%
Operating Profit Margin (Excl OI)
-2.02%
-2.14%
0.12%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 6.16% vs -10.50% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is 33.14% vs -8,550.00% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
34.82
38.20
-8.85%
Operating Profit (PBDIT) excl Other Income
-0.21
1.71
-112.28%
Interest
0.91
0.92
-1.09%
Exceptional Items
0.00
0.00
Standalone Net Profit
-1.37
-0.43
-218.60%
Operating Profit Margin (Excl OI)
-0.60%
4.48%
-5.08%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -8.85% vs -1.39% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -218.60% vs -148.31% in Mar 2024

stock-summaryCompany CV
About Chennai Meenakshi Multispeciality Hospital Ltd stock-summary
stock-summary
Chennai Meenakshi Multispeciality Hospital Ltd
Micro Cap
Healthcare Services
Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990. The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007. It is a 100-bedded hospital located in the heart of Chennai at Mylapore. The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
Company Coordinates stock-summary
Company Details
New No 70 Old No 149, Luz Church Road Mylapore Chennai Tamil Nadu : 600004
stock-summary
Tel: 91-044-42938938
stock-summary
cmmhospitals@gmail.com
Registrar Details
Cameo Corporate Services Ltd , Subramanian Buildings No 1 , Club House Road, Chennai